Venolife Duo, 500 mg 30 pcs

Pharmacotherapeutic group: Venotonizing and venoprotective agent.

CodeATH: C05СА53

Pharmacological properties

Pharmacodynamics

The combination of diosmin + hesperidin has venotonizing and angioprotective properties. The drug reduces venous distensibility and venous stasis, decreases capillary permeability and increases their resistance. The results of clinical studies confirm the pharmacological activity of the drug with respect to the indices of venous hemodynamics. Statistically reliable dose-dependent effect of the drug was demonstrated for the following venous plethysmographic parameters: venous capacity, venous distensibility, venous emptying time. An optimal dose-effect ratio is observed when taking 1000 mg per day.

The combination of diosmin + hesperidin increases venous tone: venous occlusion plethysmography showed a decrease in venous emptying time. In patients with signs of severe microcirculatory disorders, after therapy with the drug there was (statistically significant in comparison with placebo) an increase of capillary resistance evaluated by angiostereometry.

Pharmacokinetics

The main excretion of the drug is in the feces. With urine, on average, about 14% of the administered amount of the drug is excreted. The half-life period of the drug is 11 hours.

The drug undergoes active metabolism, which is confirmed by the presence of phenolic acids in urine.

Indications

Venolife Duo is indicated for the treatment of symptoms of chronic vein disease (elimination and relief of symptoms).

The therapy of symptoms of venous and lymphatic insufficiency:

– pain;

– cramping of the lower extremities;

– feeling of heaviness and tumescence in the legs;

– “tired” legs.

Treatment of manifestations of venous and lymphatic insufficiency:

– swelling of the lower extremities;

– trophic changes in the skin and subcutaneous tissue;

– venous trophic ulcers.

Symptomatic therapy of acute and chronic hemorrhoids.

Active ingredient

Purified micronized flavonoid fraction (diosmin, flavonoids in terms of hesperidin)

Composition

One tablet contains:

The active ingredient:

Purified micronized flavonoid fraction (in terms of anhydrous substance),

containing diosmin (90%) and other flavonoids (10%) – 500 mg or 1000 mg.

Auxiliary substances:

gelatin,

magnesium stearate,

microcrystalline cellulose, <

sodium carboxymethyl starch,

talc.

Film coating:

ready-mix “Vivacote” [macrogol 6000, titanium dioxide, glycerol, magnesium stearate, hypromellose, iron oxide red dye, iron oxide yellow dye],
sodium lauryl sulfate.

How to take, the dosage

Ingestion.

The recommended dose for veno-lymphatic insufficiency is 1,000 mg daily, preferably in the morning, with a meal.The tablets should be swallowed with water.

The risk on the tablet is intended solely to be divided to make it easier to swallow.

The duration of treatment may be several months (up to 12 months). If symptoms recur, the course of treatment may be repeated as recommended by the physician.

The recommended dose for acute hemorrhoids is 3000mg per day (1000mg morning, afternoon and evening) for 4 days, then 2000mg per day (1000mg morning and evening) for the next 3 days.

The recommended dose for chronic hemorrhoids is 1000 mg daily.

Interaction

No clinical studies on the study of interactions of diosmin+hesperidinz combination with other medicinal products have been conducted.

To date, no cases of drug interactions have been reported.

Special Instructions

Consultation with your doctor is recommended before taking Venolife Duo.

The treatment of acute hemorrhoids with Venolife Duo is not a substitute for the specific treatment of other anal disorders and should not last longer than indicated in the “Dosage and administration” section. If symptoms do not disappear after the recommended course of therapy, you should be examined by a proctologist who will determine further therapy.

In the presence of venous circulatory disorders, the maximum effect of therapy is achieved by combining therapy with a healthy (balanced) lifestyle: long periods of sun exposure, prolonged standing on feet, and reduction of excess body weight are preferably avoided. Walking and in some cases wearing stockings improves circulation.

Please see your doctor immediately if your condition worsens or does not improve with treatment.

Influence on ability to drive vehicles, mechanisms

No clinical studies have been conducted to study the effect of diosmin+hesperidin combination on the ability to drive and perform work requiring high mental and physical reaction speed. However, based on the available safety data, it can be concluded that diosmin + hesperidin have no effect (no significant effect) on these processes.

Contraindications

Hypersensitivity to the active ingredient or excipients contained in the drug.

It is not recommended to take the drug in lactating women.

Side effects

The side effects of diosmin+hesperidin combination observed during clinical trials were mild. Gastrointestinal disorders (diarrhea, dyspepsia, nausea, vomiting) were mostly observed.

The following side effects have been reported while taking diosmin+hesperidin combination, in the following grading: Very common (≥1/10); common (≥1/100,< 1/10); infrequent (≥1/1,000, < 1/100); rare (≥1/10,000, < 1/1,000); extremely rare(< 1/10,000), unspecified frequency (frequency cannot be calculated from available data).

Central nervous system disorders:

Rarely: dizziness, headache, general malaise.

Gastrointestinal tract disorders:

Often: diarrhea, dyspepsia, nausea, vomiting.

Infrequent: colitis.

Unspecified frequency: abdominal pain.

Skin disorders:

Rarely: skin rash, itching, urticaria.

Unspecified frequency: isolated swelling of the face, lips, eyelids. In exceptional cases, angioedema.

Inform your physician if you experience any, including any adverse reactions not mentioned in these instructions, as well as changes in laboratory values during therapy.

Overdose

No cases of overdose have been described.

Please seek medical attention immediately if you overdose.

Pregnancy use

Pregnancy

There have been no animal experiments showing teratogenic effects.

To date, there have been no reports of adverse effects when using the drug in pregnant women.

Breast-feeding

Because of the lack of data concerning excretion of the drug in the breast milk, it is not recommended for breast-feeding women to take the drug.

Impact on reproduction

Reproductive toxicity studies have shown no effect on reproductive function in rats of either sex.

Similarities

Venarus, Detralex, Phlebaven, Detravenol, Diosmin+Hesperidin, Troxactiv